Business Context and Reporting Period
Company: Nuvation Bio Inc. (NUVB)
Filing Type: Form 8-K (Current Report)
Report Date: August 6, 2026
Reporting Period: Quarter ended June 30, 2026
Context: This filing serves as a notification that the company issued a press release announcing its financial results for the second quarter of 2026. The detailed financial data is contained in Exhibit 99.1 (Press Release) and is not embedded within the text of this Form 8-K.
Key Financial Metrics
The provided text for this Form 8-K does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1) but are not disclosed in the filing body itself.
Material Changes
No material changes regarding financial performance or operations are detailed in the text of this filing. The document solely references the issuance of the quarterly results announcement.
Guidance, Outlook, and Risks
Management Commentary: The filing includes a standard disclaimer stating that the information contained in the Form 8-K and the accompanying press release shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings, except as expressly set forth by specific reference.
Guidance and Risks: The text does not provide specific forward-looking guidance, risk factors, or details on contingencies. These items are presumed to be addressed in the full press release referenced as Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 revenue, net loss, and cash burn figures.
- Verify the company's cash position and runway as disclosed in the press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full announcement.
- Confirm if the press release includes updated financial guidance for the remainder of 2026.